Incidence and Prevalence of Psoriasis in Denmark

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Incidence and Prevalence of Psoriasis in Denmark. / Egeberg, Alexander; Skov, Lone; Gislason, Gunnar H; Thyssen, Jacob P; Mallbris, Lotus.

In: Acta Dermatovenereologica, Vol. 97, No. 7, 06.07.2017, p. 808-812.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Egeberg, A, Skov, L, Gislason, GH, Thyssen, JP & Mallbris, L 2017, 'Incidence and Prevalence of Psoriasis in Denmark', Acta Dermatovenereologica, vol. 97, no. 7, pp. 808-812. https://doi.org/10.2340/00015555-2672

APA

Egeberg, A., Skov, L., Gislason, G. H., Thyssen, J. P., & Mallbris, L. (2017). Incidence and Prevalence of Psoriasis in Denmark. Acta Dermatovenereologica, 97(7), 808-812. https://doi.org/10.2340/00015555-2672

Vancouver

Egeberg A, Skov L, Gislason GH, Thyssen JP, Mallbris L. Incidence and Prevalence of Psoriasis in Denmark. Acta Dermatovenereologica. 2017 Jul 6;97(7):808-812. https://doi.org/10.2340/00015555-2672

Author

Egeberg, Alexander ; Skov, Lone ; Gislason, Gunnar H ; Thyssen, Jacob P ; Mallbris, Lotus. / Incidence and Prevalence of Psoriasis in Denmark. In: Acta Dermatovenereologica. 2017 ; Vol. 97, No. 7. pp. 808-812.

Bibtex

@article{47fc344ca8e84cf69211ca2680cdd457,
title = "Incidence and Prevalence of Psoriasis in Denmark",
abstract = "The incidence and temporal trends of psoriasis in Denmark between 2003 and 2012 were examined. There was a female predominance ranging between 50.0{\%} (2007) and 55.4{\%} (2009), and the mean age at time of diagnosis was 47.7-58.7 years. A total of 126,055 patients with psoriasis (prevalence 2.2{\%}) were identified. Incidence rates of psoriasis (per 100,000 person years) ranged from 107.5 in 2005 to a peak incidence of 199.5 in 2010. Incidence rates were higher for women, and patients aged 60-69 years, respectively. Use of systemic non-biologic agents, i.e. methotrexate, cyclosporine, retinoids, or psoralen plus ultraviolet A (PUVA) increased over the study course, and were used in 15.0{\%} of all patients. Biologic agents (efalizumab, etanercept, infliximab, adalimumab, or ustekinumab) were utilized in 2.7{\%} of patients. On a national level, incidence of psoriasis fluctuated during the 10-year study course. The relationship between psoriasis incidence and age appeared to be relatively linear, and disease prevalence was comparable to that in other European countries.",
keywords = "Adolescent, Adult, Age Distribution, Aged, Child, Child, Preschool, Denmark/epidemiology, Dermatologic Agents/therapeutic use, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Middle Aged, PUVA Therapy, Prevalence, Psoriasis/diagnosis, Sex Distribution, Time Factors, Young Adult",
author = "Alexander Egeberg and Lone Skov and Gislason, {Gunnar H} and Thyssen, {Jacob P} and Lotus Mallbris",
year = "2017",
month = "7",
day = "6",
doi = "10.2340/00015555-2672",
language = "English",
volume = "97",
pages = "808--812",
journal = "Acta Dermatovenereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato - Venereologica",
number = "7",

}

RIS

TY - JOUR

T1 - Incidence and Prevalence of Psoriasis in Denmark

AU - Egeberg, Alexander

AU - Skov, Lone

AU - Gislason, Gunnar H

AU - Thyssen, Jacob P

AU - Mallbris, Lotus

PY - 2017/7/6

Y1 - 2017/7/6

N2 - The incidence and temporal trends of psoriasis in Denmark between 2003 and 2012 were examined. There was a female predominance ranging between 50.0% (2007) and 55.4% (2009), and the mean age at time of diagnosis was 47.7-58.7 years. A total of 126,055 patients with psoriasis (prevalence 2.2%) were identified. Incidence rates of psoriasis (per 100,000 person years) ranged from 107.5 in 2005 to a peak incidence of 199.5 in 2010. Incidence rates were higher for women, and patients aged 60-69 years, respectively. Use of systemic non-biologic agents, i.e. methotrexate, cyclosporine, retinoids, or psoralen plus ultraviolet A (PUVA) increased over the study course, and were used in 15.0% of all patients. Biologic agents (efalizumab, etanercept, infliximab, adalimumab, or ustekinumab) were utilized in 2.7% of patients. On a national level, incidence of psoriasis fluctuated during the 10-year study course. The relationship between psoriasis incidence and age appeared to be relatively linear, and disease prevalence was comparable to that in other European countries.

AB - The incidence and temporal trends of psoriasis in Denmark between 2003 and 2012 were examined. There was a female predominance ranging between 50.0% (2007) and 55.4% (2009), and the mean age at time of diagnosis was 47.7-58.7 years. A total of 126,055 patients with psoriasis (prevalence 2.2%) were identified. Incidence rates of psoriasis (per 100,000 person years) ranged from 107.5 in 2005 to a peak incidence of 199.5 in 2010. Incidence rates were higher for women, and patients aged 60-69 years, respectively. Use of systemic non-biologic agents, i.e. methotrexate, cyclosporine, retinoids, or psoralen plus ultraviolet A (PUVA) increased over the study course, and were used in 15.0% of all patients. Biologic agents (efalizumab, etanercept, infliximab, adalimumab, or ustekinumab) were utilized in 2.7% of patients. On a national level, incidence of psoriasis fluctuated during the 10-year study course. The relationship between psoriasis incidence and age appeared to be relatively linear, and disease prevalence was comparable to that in other European countries.

KW - Adolescent

KW - Adult

KW - Age Distribution

KW - Aged

KW - Child

KW - Child, Preschool

KW - Denmark/epidemiology

KW - Dermatologic Agents/therapeutic use

KW - Female

KW - Humans

KW - Incidence

KW - Infant

KW - Infant, Newborn

KW - Male

KW - Middle Aged

KW - PUVA Therapy

KW - Prevalence

KW - Psoriasis/diagnosis

KW - Sex Distribution

KW - Time Factors

KW - Young Adult

U2 - 10.2340/00015555-2672

DO - 10.2340/00015555-2672

M3 - Journal article

C2 - 28417141

VL - 97

SP - 808

EP - 812

JO - Acta Dermatovenereologica

JF - Acta Dermatovenereologica

SN - 0001-5555

IS - 7

ER -

ID: 194775272